

PROVECTUS PHARMACEUTICALS INC  
Form 10QSB  
August 13, 2007

---

---

**United States  
Securities And Exchange Commission  
Washington, DC 20549**

**FORM 10-QSB**

(Mark One)

Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2007

OR

Transition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: **0-9410**

**Provectus Pharmaceuticals, Inc.**

*(Exact Name of Small Business Issuer as Specified in Its Charter)*

**Nevada**

*(State or other jurisdiction of incorporation or  
organization)*

**90-0031917**

*(I.R.S. Employer Identification Number)*

**7327 Oak Ridge Highway Suite A, Knoxville, TN 37931**

*(Address of Principal Executive Offices)*

**865/769-4011**

*(Issuer's Telephone Number, Including Area Code)*

**N/A**

*(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)*

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.

Yes  No

The number of shares outstanding of the issuer's stock, \$0.001 par value per share, as of June 30, 2007 was 45,760,619

Transitional Small Business Disclosure Format (check one): Yes  No

---

---

---

**PROVECTUS PHARMACEUTICALS, INC.**  
**(A Development-Stage Company)**

**CONSOLIDATED BALANCE SHEETS**

	June 30, 2007 (Unaudited)	December 31, 2006 (Audited)
<b>Assets</b>		
<b>Current Assets</b>		
Cash and cash equivalents	\$ 232,910	\$ 638,334
United States Treasury Notes, total face value \$6,571,371 and \$6,507,019	6,568,015	6,499,034
Prepaid expenses and other current assets	41,804	173,693
<b>Total Current Assets</b>	<b>6,842,729</b>	<b>7,311,061</b>
Equipment and Furnishings, less accumulated depreciation of \$377,349 and \$372,721	47,574	30,075
Patents, net of amortization of \$3,098,337 and \$2,762,777	8,617,108	8,952,668
Deferred loan costs, net of amortization of \$247,802 in 2006	--	3,713
Other assets	27,000	27,000
	<b>\$ 15,534,411</b>	<b>\$ 16,324,517</b>
<b>Liabilities and Stockholders' Equity</b>		
<b>Current Liabilities</b>		
Accounts payable – trade	\$ 83,396	\$ 64,935
Accrued compensation	291,646	265,929
Accrued common stock costs	--	17,550
Accrued consulting expense	69,167	42,500
Other accrued expenses	29,500	46,500
March 2005 convertible debt, net of debt discount of \$2,797 in 2006	--	364,703
<b>Total Current Liabilities</b>	<b>473,709</b>	<b>802,117</b>
<b>Stockholders' Equity</b>		
Common stock; par value \$.001 per share; 100,000,000 shares authorized; 45,760,619 and 42,452,366 shares issued and outstanding, respectively	45,761	42,452
Paid in capital	54,911,160	50,680,353
Deficit accumulated during the development stage	(39,896,219)	(35,200,405)
<b>Total Stockholders' Equity</b>	<b>15,060,702</b>	<b>15,522,400</b>

\$ 15,534,411    \$ 16,324,517

See accompanying notes to consolidated financial statements.

PROVECTUS PHARMACEUTICALS, INC.  
(A Development-Stage Company)  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(Unaudited)

	<b>Three Months Ended June 30, 2007</b>	<b>Three Months Ended June 30, 2006</b>	<b>Six Months Ended June 30, 2007</b>	<b>Six Months Ended June 30, 2006</b>	<b>Cumulative Amounts from January 17, 2002 (Inception) Through June 30, 2007</b>
<b>Revenues</b>					
OTC Product				\$	
Revenue	\$ --	\$ 394	\$ --	1,080	\$ 25,648
Medical Device					
Revenue	--	--	--	--	14,109
Total revenues	--	394	--	1,080	39,757
<b>Cost of Sales</b>					
Cost of Sales	--	252	--	691	15,216
<b>Gross Profit</b>					
Gross Profit	--	142	--	389	24,541
<b>Operating Expenses</b>					
Research and development	\$ 1,063,282	\$ 814,705	\$ 2,152,585	\$ 1,265,215	\$ 9,280,792
General and administrative	1,160,777	844,600	2,366,008	1,547,119	19,095,976
Amortization	167,780	167,780	335,560	335,560	3,098,337
Total operating loss	(2,391,839)	(1,826,943)	(4,854,153)	(3,147,505)	(31,450,564)
<b>Gain on sale of fixed assets</b>					
Gain on sale of fixed assets	--	--	--	--	55,075
<b>Loss on extinguishment of debt</b>					
Loss on extinguishment of debt	--	--	--	--	(825,867)
<b>Investment income</b>					
Investment income	84,159	87,771	169,748	110,268	423,141
<b>Interest expense</b>					
Interest expense	--	(590,259)	(11,409)	(1,592,438)	(8,098,004)
<b>Net loss</b>					
Net loss	(2,307,680)	(2,329,431)			(39,896,219)

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 10QSB

	\$	)	\$	)	\$ (4,695,814)	\$ (4,629,675)	\$	
Basic and diluted loss per common share	\$	(0.05)	\$	(0.06)	\$	(0.10)	\$	(0.13)
Weighted average number of common shares outstanding – basic and diluted		45,597,872		37,364,852		44,929,819		35,959,198

See accompanying notes to consolidated financial statements.

PROVECTUS PHARMACEUTICALS, INC.  
(A Development-Stage Company)  
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY  
(Unaudited)

	Common Stock		Paid-in capital	Accumulated deficit	Total
	Number of shares	Par value			
<b>Balance, at January 17, 2002</b>	--	\$ --	\$ --	\$ --	--
Issuance to founding shareholders	6,000,000	6,000	(6,000)	--	--
Sale of stock	50,000	50	24,950	--	25,000
Issuance of stock to employees	510,000	510	931,490	--	932,000
Issuance of stock for services	120,000	120	359,880	--	360,000
Net loss for the period from January 17, 2002 (inception) to April 23, 2002 (date of reverse merger)	--	--	--	(1,316,198)	(1,316,198)
<b>Balance, at April 23, 2002</b>	6,680,000	\$ 6,680	\$ 1,310,320	\$ (1,316,198)	\$ 802
Shares issued in reverse merger	265,763	266	(3,911)	--	(3,645)
Issuance of stock for services	1,900,000	1,900	5,142,100	--	5,144,000
Purchase and retirement of stock	(400,000)	(400)	(47,600)	--	(48,000)
Stock issued for acquisition of Valley Pharmaceuticals	500,007	500	12,225,820	--	12,226,320
Exercise of warrants	452,919	453	--	--	453
Warrants issued in connection with convertible debt	--	--	126,587	--	126,587
Stock and warrants issued for acquisition of Pure-ific	25,000	25	26,975	--	27,000
Net loss for the period from April 23, 2002 (date of reverse merger) to December 31, 2002	--	--	--	(5,749,937)	(5,749,937)
<b>Balance, at December 31, 2002</b>	9,423,689	\$ 9,424	\$ 18,780,291	\$ (7,066,135)	\$ 11,723,580
Issuance of stock for services	764,000	764	239,036	--	239,800
Issuance of warrants for services	--	--	145,479	--	145,479
Stock to be issued for services	--	--	281,500	--	281,500
Employee compensation from stock options	--	--	34,659	--	34,659
Issuance of stock pursuant to Regulation S	679,820	680	379,667	--	380,347
Beneficial conversion related to convertible debt	--	--	601,000	--	601,000
Net loss for the year ended December 31, 2003	--	--	--	(3,155,313)	(3,155,313)
<b>Balance, at December 31, 2003</b>	10,867,509	\$ 10,868	\$ 20,461,632	\$ (10,221,448)	\$ 10,251,052
Issuance of stock for services	733,872	734	449,190	--	449,923
Issuance of warrants for services	--	--	495,480	--	495,480
Exercise of warrants	132,608	133	4,867	--	5,000
Employee compensation from stock options	--	--	15,612	--	15,612
Issuance of stock pursuant to Regulation S	2,469,723	2,469	790,668	--	793,137
Issuance of stock pursuant to Regulation D	1,930,164	1,930	1,286,930	--	1,288,861
Beneficial conversion related to convertible debt	--	--	360,256	--	360,256
Issuance of convertible debt with warrants	--	--	105,250	--	105,250
Repurchase of beneficial conversion feature	--	--	(258,345)	--	(258,345)
Net loss for the year ended December 31, 2004	--	--	--	(4,344,525)	(4,344,525)
<b>Balance, at December 31, 2004</b>	16,133,876	\$ 16,134	\$ 23,711,540	\$ (14,565,973)	\$ 9,161,701
Issuance of stock for services	226,733	227	152,058	--	152,285
Issuance of stock for interest payable	263,721	264	195,767	--	196,031

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 10QSB

Issuance of warrants for services	--	--	1,534,405	--	1,534,405
Issuance of warrants for contractual obligations	--	--	985,010	--	985,010
Exercise of warrants and stock options	1,571,849	1,572	1,438,223	--	1,439,795
Employee compensation from stock options	--	--	15,752	--	15,752
Issuance of stock pursuant to Regulation D	6,221,257	6,221	6,506,955	--	6,513,176
Debt conversion to common stock	3,405,541	3,405	3,045,957	--	3,049,795
Issuance of warrants with convertible debt	--	--	1,574,900	--	1,574,900
Beneficial conversion related to convertible debt	--	--	1,633,176	--	1,633,176
Beneficial conversion related to interest expense	--	--	39,259	--	39,529
Repurchase of beneficial conversion feature	--	--	(144,128)	--	(144,128)
Net loss for the year ended 2005	--	--	--	(11,763,853)	(11,763,853)
<b>Balance, at December 31, 2005</b>	27,822,977	\$ 27,823	\$40,689,144	\$ (26,329,826)	\$14,387,141
Issuance of stock for services	719,246	719	676,024	--	676,743
Issuance of stock for interest payable	194,327	195	183,401	--	183,596
Issuance of warrants for services	--	--	370,023	--	370,023
Exercise of warrants and stock options	1,245,809	1,246	1,188,570	--	1,189,816
Employee compensation from stock options	--	--	1,862,456	--	1,862,456
Issuance of stock pursuant to Regulation D	10,092,495	10,092	4,120,329	--	4,130,421
Debt conversion to common stock	2,377,512	2,377	1,573,959	--	1,576,336
Beneficial conversion related to interest expense	--	--	16,447	--	16,447
Net loss for the year ended 2006	--	--	--	(8,870,579)	(8,870,579)
<b>Balance, at December 31, 2006</b>	42,452,366	\$ 42,452	\$50,680,353	\$ (35,200,405)	\$15,522,400
Issuance of stock for services	50,000	50	83,950	--	84,000
Issuance of stock for interest payable	1,141	1	1,257	--	1,258
Issuance of warrants for services	--	--	174,118	--	174,118
Exercise of warrants and stock options	390,295	390	332,522	--	332,912
Employee compensation from stock options	--	--	1,426,190	--	1,426,190
Issuance of stock pursuant to Regulation D	2,376,817	2,378	1,845,760	--	1,848,138
Debt conversion to common stock	490,000	490	367,010	--	367,500
Net loss for the six months ended June 30, 2007	--	--	--	(4,695,814)	(4,695,814)
<b>Balance, at June 30, 2007</b>	45,760,619	\$ 45,761	\$54,911,160	\$ (39,896,219)	\$15,060,702

See accompanying notes to consolidated financial statements.



**PROVECTUS PHARMACEUTICALS, INC.**  
**(A Development-Stage Company)**  
**CONSOLIDATED STATEMENTS OF CASH FLOW**  
**(Unaudited)**

	Six Months Ended June 30, 2007	Six Months Ended June 30, 2006	Cumulative Amounts from January 17, 2002 (Inception) through June 30, 2007
<b>Cash Flows From Operating Activities</b>			
Net loss	\$ (4,695,814)	\$ (4,629,675)	\$ (39,896,219)
Adjustments to reconcile net loss to net cash used in operating activities			
Depreciation	4,628	1,944	400,350
Amortization of patents	335,560	335,560	3,098,337
Amortization of original issue discount	2,797	851,365	3,845,721
Amortization of commitment fee	--	--	310,866
Amortization of prepaid consultant expense	84,019	--	1,295,226
Amortization of deferred loan costs	3,713	646,192	2,261,584
Accretion of United States Treasury Notes	(101,167)	(71,281)	(283,365)
Loss on extinguishment of debt	--	--	825,867
Loss on exercise of warrants	--	--	236,146
Beneficial conversion of convertible interest	--	16,447	55,976
Convertible interest	1,258	82,082	389,950
Compensation through issuance of stock options	1,426,190	715,666	3,354,669
Compensation through issuance of stock	--	--	932,000
Issuance of stock for services	110,667	26,100	6,105,698
Issuance of warrants for services	174,118	58,400	717,287
Issuance of warrants for contractual obligations	--	--	985,010
Gain on sale of equipment	--	--	(55,075)
(Increase) decrease in assets			
Officer/Director advance	--	(273,247)	--
Prepaid expenses and other current assets	47,870	23,192	(41,804)
Increase (decrease) in liabilities			
Accounts payable	18,461	14,038	79,751
Accrued expenses	8,717	(19,253)	541,943
<b>Net cash used in Operating Activities</b>	<b>(2,578,983)</b>	<b>(2,222,470)</b>	<b>(14,840,082)</b>
<b>Cash Flows from investing activities</b>			
Proceeds from sale of fixed asset	--	--	180,075
Capital expenditures	(22,127)	(8,601)	(62,049)
Proceeds from investments	10,005,000	2,000,000	21,005,000
Purchase of investments	(9,972,814)	(6,423,379)	(27,289,650)
<b>Net cash used in Investing Activities</b>	<b>10,059</b>	<b>(4,431,980)</b>	<b>(6,166,624)</b>

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 10QSB

Cash Flows from Financing Activities

Net proceeds from loans from stockholder	--	--	174,000
Proceeds from convertible debt	--	--	6,706,795
Net proceeds from sale of common stock	1,830,588	525,112	14,979,081
Proceeds from exercise of warrants and stock options	332,912	472,359	2,731,830
Cash paid to retire convertible debt	--	--	(2,385,959)
Cash paid for deferred loan costs	--	--	(747,612)
Premium paid on extinguishments of debt	--	--	(170,519)
Purchase and retirement of common stock	--	--	(48,000)
Net cash provided by financing activities	2,163,500	997,471	21,239,616
Net change in cash and cash equivalents	\$ (405,424)	\$ (5,656,979)	\$ 232,910
Cash and cash equivalents, at beginning of period	\$ 638,334	\$ 6,878,990	--
Cash and cash equivalents, at end of period	\$ 232,910	\$ 1,222,011	\$ 232,910

Supplemental Disclosure of Noncash Investing and Financing Activities:

June 30, 2007

1. Debt converted to common stock of \$367,500
2. Payment of accrued interest through the issuance of stock of \$1,258
3. Issuance of stock for stock issuance costs of \$17,550 incurred in 2006
4. Stock committed to be issued for services of \$26,667 accrued at June 30, 2007

June 30, 2006

1. Debt converted to common stock of \$1,243,836
2. Payment of accrued interest through the issuance of stock of \$143,490
3. Issuance of stock for stock issuance costs of \$964,676 incurred in 2005
4. Stock committed to be issued for services of \$650,643 accrued at December 31, 2005 and issued in 2006

See accompanying notes to consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  
(unaudited)

**1. Basis of Presentation**

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information pursuant to Regulation S-B. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2007 are not necessarily indicative of the results that may be expected for the year ended December 31, 2007.

**2. Recapitalization and Merger**

Provectus Pharmaceuticals, Inc., formerly known as "Provectus Pharmaceutical, Inc." and "SPM Group, Inc.," was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate.

On April 1, 2002, SPM Group changed its name to "Provectus Pharmaceutical, Inc." and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation ("PPI"). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to "Provectus Pharmaceuticals, Inc." ("Provectus" or "the Company"), and PPI became a wholly owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI.

On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation "Xantech Pharmaceuticals, Inc." Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions.

**3. Basic and Diluted Loss Per Common Share**

Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options, warrants, and convertible debt as they are antidilutive. Potential common shares excluded from the calculation at June 30, 2007 are 26,563,081 warrants, 9,084,419 options.

**4. Equity and Debt Transactions**

(a) In January 2007, the Company issued 150,000 shares committed to be issued at December 31, 2006 for shares sold in 2006. In January 2007, the Company issued 15,000 shares committed to be issued at December 31, 2006 for

common stock costs related to shares sold in 2006. The total value for these shares was \$17,550 which was based on the market value of the shares issued and was recorded as an accrued liability at December 31, 2006. In January and February 2007, the Company completed a private placement transaction with 6 accredited investors pursuant to which the Company sold a total of 265,000 shares of common stock at a purchase price of \$1.00 per share, for an aggregate purchase price of \$265,000. The Company paid \$29,150 and issued 26,500 shares of common stock at a fair market value of \$32,130 to Chicago Investment Group of Illinois, L.L.C. as a placement agent for this transaction. The cash costs have been off-set against the proceeds received. Also in January and February 2007, the Company completed a private placement transaction with 13 accredited investors pursuant to which the Company sold a total of 1,745,743 shares of common stock at a purchase price of \$1.05 per share, for an aggregate purchase price of \$1,833,031. The Company paid \$238,293 and issued 174,574 shares of common stock at a fair market value of \$200,760 to Network 1 Financial Securities, Inc. as placement agent for this transaction. The cash costs have been off-set against the proceeds received.

(b) In January 2007, the Company entered into a separate debt conversion agreement with two of its March 2005 accredited investors for \$245,833 of convertible debt which was converted into 327,777 shares of common stock at \$0.75 per share. In February 2007 the Company entered into a separate debt conversion agreement with two of its March 2005 accredited investors for \$121,667 of convertible debt which was converted into 162,223 shares of common stock at \$0.75 per share.

In February 2007, the remaining total debt discount has been amortized, which is \$2,797. In February 2007 the remaining deferred loan costs have been amortized, which is \$3,713.

At June 30, 2007 the Company had no remaining principal or accrued interest owed to holders of the March 2005 convertible debentures due on March 31, 2007.

The Company chose to pay a portion of the quarterly interest due at February 28, 2007 in common stock instead of cash. The accrued interest not paid in cash that was due February 28, 2007 of \$1,109 was converted into 1,141 shares of common stock resulting in additional interest expense of \$149. 358 of these shares were issued on January 25, 2007 and the remaining shares of 783 were issued on February 28, 2007.

(c) During the three months ended March 31, 2007, \$42,010 of prepaid consulting costs relating to warrants issued in 2006 have been charged to operations. During the three months ended June 30, 2007, the remaining prepaid consulting costs of \$42,009 relating to warrants issued in 2006 have been charged to operations. During the three months ended March 31, 2007, the Company issued 85,000 warrants to consultants in exchange for services. Consulting costs charged to operations were \$75,933. During the three months ended June 30, 2007, the Company issued 85,000 warrants to consultants in exchange for services. Consulting costs charged to operations were \$98,185. In April and May 2007, 260,000 warrants were exercised for \$196,900 resulting in 260,000 shares issued. In May 2007, 10,000 warrants were forfeited.

(d) In May 2007, the Company issued 50,000 shares to consultants in exchange for services. Consulting costs charged to operations were \$84,000. As of June 30, 2007, the Company is also committed to issue 16,667 shares to consultants in exchange for services. At June 30, 2007, these shares have a value of \$26,667 and have been included in accrued consulting expense.

## 5. Stock-Based Compensation

One employee of the Company exercised a total of 120,920 options during the three months ended March 31, 2007 at an exercise price of \$1.10 per share of common stock for \$133,012. Another employee of the Company exercised a total of 9,375 options during the three months ended March 31, 2007 at an exercise price of \$0.32 per share of common stock for \$3,000. On June 21, 2007, the Company issued 200,000 stock options to its Members of the Board. The options vested on the date of grant. The exercise price is the fair market price on the date of issuance, and all options were outstanding at June 30, 2007.

Effective January 1, 2006, the Company adopted FASB 123R. This change in accounting replaces existing requirements under FASB 123 and eliminates the ability to account for share-based compensation transaction using APB 25. The compensation cost relating to share-based payment transactions will be measured based on the fair value of the equity or liability instruments issued. For purposes of estimating the fair value of each stock option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the company's common stock (as determined by reviewing its historical public market closing prices). Because the Company's employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options or restricted stock units. Included in the results for the three and six months ended June 30, 2007, is \$852,795 and \$1,426,190, respectively, of stock-based compensation expense which relates to the fair value of stock options. Included in the results for the three and six months ended June 30, 2006, is \$453,833 and \$715,666, respectively, of stock-based compensation expense which relates to the fair value of stock options.

## **6. Cash Balance Defined Benefit Plan and Trust**

In January 2007 the Company established the Provectus Pharmaceuticals, Inc. Cash Balance Defined Benefit Plan and Trust (the "Plan"), effective January 1, 2007, for the exclusive benefit of its four employees and their beneficiaries. The Plan was fully funded for 2007 in January totaling \$324,000 or \$81,000 per employee. The Plan contributions vest equally over six years and the Plan will be funded at approximately the same level each year in accordance with the provisions of the Plan.

## **Item 2. Management's Discussion and Analysis or Plan of Operation.**

The following discussion is intended to assist in the understanding and assessment of significant changes and trends related to our results of operations and our financial condition together with our consolidated subsidiaries. This discussion and analysis should be read in conjunction with the consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-QSB. Historical results and percentage relationships set forth in the statement of operations, including trends which might appear, are not necessarily indicative of future operations.

## **Capital Structure**

Our ability to continue as a going concern is assured due to our financing completed during 2006. At the current rate of expenditures, we will not need to raise additional capital until 2008, although our existing funds are sufficient to meet anticipated needs throughout 2008.

We have implemented our integrated business plan, including execution of the current and next phases in clinical development of our pharmaceutical products and continued execution of research programs for new research initiatives.

We intend to proceed as rapidly as possible with the asset sale and licensure of our OTC products that can be sold with a minimum of regulatory compliance and with the further development of revenue sources through licensing of our existing medical device and biotech intellectual property portfolio. Although we believe that there is a reasonable basis for our expectation that we will become profitable due to the asset sale and licensure of our OTC products, we cannot assure you that we will be able to achieve, or maintain, a level of profitability sufficient to meet our operating expenses.

Our current plans include continuing to operate with our four employees during the immediate future, but we have added additional consultants and anticipate adding more consultants in the next 12 months. Our current plans also include minimal purchases of new property, plant and equipment, and increased research and development for additional clinical trials.

## **Plan of Operation**

With the reorganization of Provectus and PPI and the acquisition and integration into the company of Valley and Pure-ific, we believe we have obtained a unique combination of OTC products and core intellectual properties. This combination represents the foundation for an operating company that we believe will provide both profitability and long-term growth. In 2007, we will carefully control expenditures in preparation for the asset sale and licensure or spin out of our OTC products, medical device and biotech technologies, and we will issue equity only when it makes sense to the company and primarily for purposes of attracting strategic investors.

In the short term, we intend to develop our business by selling the OTC assets and licensing our existing OTC products, principally Pure-Stick, GloveAid and Pure-ific. We are also now considering a spin out of the wholly owned subsidiary that contains the OTC assets. We will also sell and/or license our medical device and biotech technologies. In the longer term, we expect to continue the process of developing, testing and obtaining the approval of the U. S. Food and Drug Administration of prescription drugs in particular. Additionally, we have restarted our research programs that will identify additional conditions that our intellectual properties may be used to treat and additional treatments for those and other conditions.

## **Comparison of Three and Six Months Ended June 30, 2007 and June 30, 2006.**

### **Revenues**

OTC Product Revenue decreased by \$394 in the three months ended June 30, 2007 to \$-0- from \$394 in the three months ended June 30, 2006. OTC Product Revenue decreased by \$1,080 in the six months ended June 30, 2007 to \$-0- from \$1,080 in the six months ended June 30, 2006. We have discontinued our proof of concept program in November 2006 and have therefore ceased selling our OTC products.

### **Research and development**

We have continued to make significant progress with the major research and development projects expected to be ongoing in the next 12 months. Our expanded Phase 1 metastatic melanoma clinical trial and the second part of our expanded Phase 1 breast carcinoma clinical trial was completed in April 2007 for approximately \$1,000,000 in the aggregate, most of which has been expended in 2005 and 2006. The planning phase for the expected Phase 2 trial in metastatic melanoma has been completed which will cost approximately \$3,000,000 through 2008. This includes expenditures in 2007 to significantly advance the proposed metastatic melanoma study which may provide pivotal efficacy. Additionally, we plan \$1,000,000 of expenditures in 2007 to substantially advance our work with other oncology indications. Our Phase 2 psoriasis trial is expected to commence in 2007 and will cost approximately \$1,500,000 over 12 to 24 months. Our Phase 1 liver cancer trial is expected to cost approximately \$500,000 in total, and is expected to commence in 2007 as well.



Research and development costs of \$1,063,282 for the three months ended June 30, 2007 included depreciation expense of \$2,314, consulting and contract labor of \$166,755, lab supplies and pharmaceutical preparations of \$84,263, insurance of \$24,088, legal of \$90,925, payroll of \$680,016, and rent and utilities of \$14,921. Research and development costs of \$814,705 for the three months ended June 30, 2006 included depreciation expense of \$1,079, consulting and contract labor of \$83,635, lab supplies and pharmaceutical preparations of \$124,950, insurance of \$18,201, legal of \$53,150, payroll of \$519,786, and rent and utilities of \$13,904. The increase in consulting and contract labor is primarily the result of expense necessary to prepare for advanced clinical trials in final preparations to commence in 2007. The increase in payroll is the result of raises, and the impact of stock option expense for stock options issued at the end of June 2006 which vest over a three-year period.

Research and development costs of \$2,152,585 for the six months ended June 30, 2007 included depreciation expense of \$4,628, consulting and contract labor of \$304,493, lab supplies and pharmaceutical preparations of \$99,011, insurance of \$43,656, legal of \$143,755, payroll of \$1,525,984, and rent and utilities of \$31,058. Research and development costs comprising the total of \$1,265,215 for the six months ending June 30, 2006 included depreciation expense of \$1,944, consulting and contract labor of \$138,853, lab supplies and pharmaceutical preparations of \$142,167, insurance of \$26,409, legal of \$97,772, payroll of \$830,622, and rent and utilities of \$27,448. The increase in consulting and contract labor is primarily the result of expense necessary to prepare for advanced clinical trials in final preparations to commence in 2007. The increase in payroll is the result of bonuses, pension expense, raises, and the impact of stock option expense for stock options issued at the end of June 2006 which vest over a three-year period.

### **General and administrative**

General and administrative expenses increased by \$316,177 in the three months ended June 30, 2007 to \$1,160,777 from \$844,600 for the three months ended June 30, 2006. The increase resulted primarily from higher payroll expenses for general corporate purposes as a result of raises and the impact of stock option expense for stock options issued at the end of June 2006 which vest over a three-year period. Additionally, consulting expense increased \$125,000 due to higher investor and public relations expense.

General and administrative expenses increased by \$818,889 in the six months ended June 30, 2007 to \$2,366,008 from \$1,547,119 for the six months ended June 30, 2006. The increase resulted primarily from higher payroll expenses for general corporate purposes as a result of bonuses, pension expense, raises and the impact of stock option expense for stock options issued at the end of June 2006 which vest over a three-year period. Additionally, consulting expense increased \$212,000 due to higher external accounting expense, Sarbanes-Oxley Section 404 implementation expense, and investor and public relations expense.

### **Cash Flow**

As of June 30, 2007, we held approximately \$6,800,000 in cash and short-term United States Treasury Notes. At our current cash expenditure rate, this amount will be sufficient to meet our current and planned needs in 2007 and 2008. We have been increasing our expenditure rate by accelerating some of our research programs for new research initiatives; in addition, we are seeking to improve our cash flow through the asset sale and licensure of our OTC products. However, we cannot assure you that we will be successful in selling the OTC assets and licensing our existing OTC products. Moreover, even if we are successful in improving our current cash flow position, we nonetheless plan to require additional funds to meet our long-term needs in 2009 and beyond. We anticipate these funds will come from the proceeds of private placements, the exercise of existing warrants outstanding, or public offerings of debt or equity securities.

### **Capital Resources**

As noted above, our present cash flow is currently sufficient to meet our short-term operating needs. Excess cash will be used to finance the current and next phases in clinical development of our pharmaceutical products. We anticipate that any required funds for our operating and development needs beyond 2008 will come from the proceeds of private placements, the exercise of existing warrants outstanding, or public offerings of debt or equity securities. While we believe that we have a reasonable basis for our expectation that we will be able to raise additional funds, we cannot assure you that we will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to shareholders. For further information on funding sources, please see the notes to our financial statements included in this report.

## Critical Accounting Policies

### Patent Costs

Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining life of the patent. The patents are being amortized over the remaining lives of the patents, which range from 11-15 years. Annual amortization of the patents is expected to be approximately \$671,000 per year for the next five years.

### Long-Lived Assets

The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell.

### Stock Based Compensation

On December 16, 2004, the Financial Accounting Standards Board ("FASB") released FASB Statement No. 123 (revised 2004), "Share-Based Payment, ("FASB 123R)". These changes in accounting replace existing requirements under FASB Statement No. 123, "Accounting for Stock-Based Compensation" ("FASB 123"), and eliminates the ability to account for share-based compensation transaction using APB Opinion No.25, "Accounting for Stock Issued to Employees" ("APB 25"). The compensation cost relating to share-based payment transactions will be measured based on the fair value of the equity or liability instruments issued. This Statement did not change the accounting for similar transactions involving parties other than employees.

The Company adopted FASB 123R effective January 1, 2006 under the modified prospective method, which recognizes compensation cost beginning with the effective date (a) based on the requirements of FASB 123R for all share-based payments granted after the effective date and to awards modified, repurchased, or cancelled after that date and (b) based on the requirements of FASB 123 for all awards granted to employees prior to the effective date of FASB 123R that remain unvested on the effective date. There was no cumulative effect of initially applying this Statement for the Company. At June 30, 2007 the Company has estimated that an additional \$704,581 will be expensed over the applicable remaining vesting periods for all share-based payments granted to employees on or before December 31, 2005 which remained unvested on January 1, 2006.

The compensation cost relating to share-based payment transactions will be measured based on the fair value of the equity or liability instruments issued and will be expensed on a straight-line basis. For purposes of estimating the fair value of each stock option or restricted stock unit on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the company's common stock (as determined by reviewing its historical public market closing prices). Because the Company's employee stock options and restricted stock units have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options or restricted stock units.

### **Forward-Looking Statements**

This Quarterly Report on Form 10-QSB contains forward-looking statements regarding, among other things, our anticipated financial and operating results. Forward-looking statements reflect our management's current assumptions, beliefs, and expectations. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," and similar expressions are intended to identify forward-looking statements. While we believe that the expectations reflected in our forward-looking statements are reasonable, we can give no assurance that such expectations will prove correct. Forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from the future results, performance, or achievements expressed in or implied by any forward-looking statement we make. Some of the relevant risks and uncertainties that could cause our actual performance to differ materially from the forward-looking statements contained in this report are discussed below under the heading "Risk Factors" and elsewhere in this Quarterly Report on Form 10-QSB. We caution investors that these discussions of important risks and uncertainties are not exclusive, and our business may be subject to other risks and uncertainties which are not detailed there.

Investors are cautioned not to place undue reliance on our forward-looking statements. We make forward-looking statements as of the date on which this Quarterly Report on Form 10-QSB is filed with the SEC, and we assume no obligation to update the forward-looking statements after the date hereof whether as a result of new information or events, changed circumstances, or otherwise, except as required by law.

### **Item 3. Controls and Procedures.**

(a) Evaluation of Disclosure Controls and Procedures. Our chief executive officer and chief financial officer have evaluated the effectiveness of the design and operation of our "disclosure controls and procedures" (as that term is defined in Rule 13a-15(e) under the Exchange Act) as of June 30, 2007, the end of the fiscal quarter covered by this Quarterly Report on Form 10-QSB. Based on that evaluation, the chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that material information relating to the Company and the Company's consolidated subsidiaries is made known to such officers by others within these entities, particularly during the period this Quarterly Report on Form 10-QSB was prepared, in order to allow timely decisions regarding required disclosure.

(b) Changes in Internal Controls. There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-QSB that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

### Item 1. Legal Proceedings.

The Company was not involved in any legal proceedings during the fiscal quarter covered by this Quarterly Report of Form 10-QSB.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities

None.

### Item 3. Defaults Upon Senior Securities.

None.

### Item 4. Submission of Matters to a Vote of Security Holders.

(a) Our annual meeting of shareholders was held on June 21, 2007.

(b) The following is a list of all nominees for Director of the Company who were elected at the annual meeting and whose term of office continued after the annual meeting:

H. Craig Dees  
Timothy D. Scott  
Eric A. Wachter  
Stuart R. Fuchs

(c) There were present at the annual meeting in person or by proxy 29,840,046 shares of our common stock out of a total of 45,450,619 shares of our common stock issued and outstanding and entitled to vote at the annual meeting.

(d) The results of the vote of the shareholders taken at the annual meeting by ballot and by proxy as solicited by us on behalf of the board of directors for the election of the nominees for our board of directors were as follows:

Nominee	For	Withheld Authority
H. Craig Dees	29,767,894	55,152
Timothy C. Scott	29,783,394	39,652
Eric A. Wachter	29,783,994	39,052
Stuart Fuchs	29,715,294	90,552

### Item 5. Other Information.

None.

### Item 6. Exhibits

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 10QSB

31.1 Certification Pursuant to Rule 13a-14(a) (Section 302 Certification), dated August 10, 2007, executed by H. Craig Dees, Ph.D., Chief Executive Officer of the Company.

31.2 Certification Pursuant to Rule 13a-14(a) (Section 302 Certification), dated August 10, 2007, executed by Peter R. Culpepper, Chief Financial Officer of the Company.

32.1 Certification Pursuant to 18 U.S.C. ss. 1350 (Section 906 Certification), dated August 10, 2007, executed by H. Craig Dees, Ph.D., Chief Executive Officer of the Company, and Peter R. Culpepper, Chief Financial Officer of the Company.

**Signatures**

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Provectus Pharmaceuticals, Inc.

By:/s/ H. Craig Dees, Ph.D.

H. Craig

Dees, Ph.D. Chief Executive Officer

Date: August 10, 2007

12

---

**EXHIBIT INDEX**

**Exhibit No.   Description**

31.1   Certification Pursuant to Rule 13a-14(a) (Section 302 Certification), dated August 10, 2007, executed by H. Craig Dees, Ph.D., Chief Executive Officer of the Company.

31.2   Certification Pursuant to Rule 13a-14(a) (Section 302 Certification), dated August 10, 2007, executed by Peter R. Culpepper, Chief Financial Officer of the Company.

32.1   Certification Pursuant to 18 U.S.C. ss. 1350 (Section 906 Certification), dated August 10, 2007, executed by H. Craig Dees, Ph.D., Chief Executive Officer of the Company, and Peter R. Culpepper, Chief Financial Officer of the Company.